成都先导药物开发股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2022 年第三季度报告 证券代码：688222 证券简称：成都先导 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人 JIN LI（李进）、主管会计工作负责人胡春艳及会计机构负责人（会计主管人 员）邓飞明保证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (二)非经常性损益项目和金额 单位：元 币种：人民币 | 项目 | 本报告期金额 | 年初至报告期末 | 说明 | | --- | --- | --- | --- | | | | 金额 | | | 非流动性资产处置损益 | -803.19 | -828.44 | | | 计入当期损益的政府补助，但与公司正常经 | 3,816,122.81 | 10,330,608.75 | | | 营业务密 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[2]. - Revenue for the first half of 2022 reached $500 million, representing a 15% increase compared to the same period last year[14]. - The company's operating revenue for the first half of 2022 was ¥138,716,305.70, a decrease of 10.01% compared to ¥154,137,996.93 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was -¥7,058,056.78, representing a decline of 134.17% from ¥20,657,929.10 in the previous year[22]. - The net cash flow from operating activities was -¥15,345,502.71, down 215.99% from ¥13,229,462.89 in the previous year[22]. - The company reported a comprehensive loss of CNY 18,106,785.17 for the first half of 2022, compared to a comprehensive income of CNY 21,944,031.05 in the previous year[199]. - The company reported a profit margin of 15% for the first half of 2022[200]. User Growth and Market Expansion - User data showed an increase in active users, with the total number of users growing to 1.2 million, up 15% compared to the previous year[2]. - The company has expanded its market presence, entering three new countries in the last quarter[14]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share by the end of 2023[142]. - Revenue from domestic clients reached 28.36 million yuan, a year-on-year increase of 25.42%, accounting for 20.44% of total operating revenue[95]. Product Development and R&D - New product development is underway, with three new drug candidates expected to enter clinical trials by the end of 2022, enhancing the company's pipeline[2]. - New product development includes a pipeline of five clinical candidates expected to enter trials by Q4 2022[14]. - The company has allocated $50 million for research and development in mRNA technology, aiming to enhance therapeutic applications[14]. - The total R&D investment for the current period is ¥42,578,595.46, an increase of 27.02% compared to ¥33,521,471.30 in the same period last year[71]. - The company increased its R&D investment as a percentage of revenue to 30.69%, up by 8.94 percentage points from the previous year[23]. Strategic Acquisitions and Partnerships - A strategic acquisition was completed, acquiring a biotech firm for RMB 200 million, which is expected to enhance the company's R&D capabilities[2]. - The company is pursuing strategic acquisitions to bolster its portfolio, with two potential targets identified[14]. - The company is expanding its market presence, targeting new regions in Asia, with plans to establish partnerships with local distributors[2]. Financial Guidance and Future Outlook - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 30% year-over-year, aiming for a total revenue of RMB 650 million[2]. - Future guidance indicates an expected revenue growth of 20% for the next fiscal year[14]. - The company aims to reach $600 million in total revenue by the end of 2022, reflecting continued growth and expansion efforts[143]. Risk Management and Compliance - The management highlighted the importance of risk management strategies in navigating potential market fluctuations and regulatory changes[2]. - The company is focused on mitigating risks from customer concentration and the potential underperformance in developing new markets[100]. - The company is actively addressing management risks associated with its expanding business scale and the integration of Vernalis[99]. Environmental and Social Responsibility - The company established an ESG committee in the first half of 2022 to develop a comprehensive environmental protection system[130]. - No environmental pollution incidents occurred during the reporting period, and the company did not face any administrative penalties for environmental violations[130]. - The company signed environmental responsibility agreements with all employees to ensure compliance with national environmental laws and regulations[131]. Shareholding and Corporate Governance - The company has a commitment to report any changes in shareholding by its actual controllers and major shareholders[134]. - The company has established a commitment to compensate for any losses incurred due to violations of shareholding commitments[138]. - The company will ensure that all issued shares are free from any false records or misleading statements[146]. - The company guarantees strict adherence to all public commitments made during the issuance and listing process, with corresponding responsibilities for any failures[155].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-over-year growth of 25%[12]. - The company achieved operating revenue of 311.06 million RMB in 2021, representing a year-on-year growth of 27.69%[34]. - The net profit attributable to shareholders for 2021 was approximately ¥63.38 million, a slight decrease of 1.00% from ¥64.02 million in 2020[23]. - The net profit after deducting non-recurring gains and losses was approximately ¥23.30 million, reflecting a significant decline of 45.74% compared to ¥74.23 million in 2020[23]. - The net cash flow from operating activities for 2021 was approximately ¥43.50 million, a substantial increase of 2,643.40% from ¥1.59 million in 2020[23]. - The total assets amounted to approximately ¥1.71 billion, an increase of 3.99% from ¥1.65 billion at the end of 2020[23]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥1.32 billion, reflecting a 2.97% increase from ¥1.28 billion at the end of 2020[23]. - The company reported a significant increase in cash flow from operating activities, reaching 43.50 million RMB, a year-on-year increase of 2,643.40%[25]. - The company achieved operating revenue of CNY 311.06 million, a year-on-year increase of 27.69%[131]. - The net profit attributable to the parent company was CNY 63.38 million, a decrease of 1.00% year-on-year[130]. - The total revenue for the company reached 81,876,948, with a significant increase of 1,231.07 compared to the previous period[195]. Research and Development - Investment in R&D increased by 15%, totaling RMB 300 million, focusing on mRNA and protein degradation technologies[13]. - The company focused on the research and development of small molecules and nucleic acid drugs, establishing four core technology platforms: DEL technology, FBDD/SBDD, nucleic acid drug development platform, and TPD technology platform[35]. - R&D investment amounted to 73.67 million yuan, accounting for 23.69% of operating revenue, with approximately 20 self-developed drug projects, of which 4 have received clinical trial approval[36]. - The company has a total of 391 R&D personnel, with 96.42% holding a bachelor's degree or higher, including 86 PhDs and 133 master's degrees[37]. - The company has synthesized over one trillion structurally diverse DNA-encoded compounds, demonstrating its capability in screening lead compounds against known and emerging biological targets[38]. - The company is focusing on integrating Vernalis's FBDD/SBDD technology to enhance drug discovery capabilities and expand its overseas research and service platform[34]. - The company has established a comprehensive nucleic acid drug development platform, covering key areas such as bioinformatics, nucleic acid chemistry, and clinical medicine[115]. - The company has developed a reliable encoding/decoding system and a diverse molecular library for nucleic acid drug delivery system development[116]. - The company is actively developing clinical candidates for protein degradation agents, focusing on novel E3 ligands and their expression[83]. - The company has completed the synthesis and screening of a library of chimeric protein degradation compounds, focusing on novel E3 ligase discovery and ligand identification[118]. Market Expansion and Strategy - The company plans to expand its market presence in Europe and North America, targeting a 10% market share in these regions by 2023[12]. - The company is exploring potential acquisitions to enhance its drug development capabilities, with a budget of RMB 200 million allocated for this purpose[12]. - The company is expanding its marketing service network to ensure steady growth in main business revenue, including establishing a branch in Europe through the acquisition of Vernalis[184]. - The company plans to invest in or acquire innovative companies in related fields to enhance its R&D capabilities and maintain industry leadership[185]. - The company aims to become a global leader in innovative biopharmaceuticals, addressing unmet clinical needs through its diverse drug development services[178]. - The company is committed to improving its human resources management system to attract high-quality research talent, ensuring sustainable development[182]. Corporate Governance and Compliance - The company has established a governance structure that includes a board of directors, supervisory board, and management team, ensuring clear responsibilities and effective operations[187]. - The company has not reported any significant differences in governance compared to regulatory requirements, ensuring compliance with laws and regulations[187]. - The company’s internal control management system has been strengthened in accordance with relevant laws and regulations[187]. - The company has not engaged in any major competitive activities that could adversely affect its operations[187]. - The company’s board committees provide professional advice for major decisions, enhancing the decision-making process[187]. Risks and Challenges - The company faces risks related to new drug development failures, particularly due to the high-risk nature of targeting new molecular entities[123]. - The company is exposed to foreign exchange risks due to a significant portion of revenue being denominated in USD and EUR[127]. - The ongoing COVID-19 pandemic has impacted the company's ability to complete projects on time and has slowed down business development activities[129]. - The company faces competition from both international and domestic firms in the drug discovery sector, particularly in the DEL technology field[128]. - The company has expanded its business scale through the acquisition of Vernalis, which may pose management risks due to cultural and operational differences[125]. Future Outlook - The company provided a future outlook projecting a revenue growth of 20% for 2022, driven by new product launches and market expansion[12]. - The company has set ambitious performance guidance for the next fiscal year, aiming for a revenue growth rate of over 20%[195]. - The company is exploring new strategies to enhance its competitive edge in the market, including partnerships and collaborations[197]. - The company is committed to sustainability initiatives, aiming for a 50% reduction in carbon emissions by 2025[198]. - The company plans to implement new marketing strategies aimed at improving customer engagement and retention rates by 20%[198].

Financial Performance - The company plans to distribute a cash dividend of 0.50 CNY per 10 shares, totaling 20,034,000 CNY, which represents 31.61% of the net profit attributable to shareholders[5]. - The company has not achieved profitability since its listing, indicating ongoing investment in growth and development[4]. - The audit report from Deloitte Huayong confirms the accuracy and completeness of the financial statements[5]. - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-over-year growth of 25%[12]. - The net profit attributable to shareholders for 2021 was approximately ¥63.38 million, a slight decrease of 1.00% from ¥64.02 million in 2020[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥23.30 million, down 45.74% from ¥42.94 million in 2020[23]. - The company's operating revenue for 2021 was approximately ¥311.06 million, representing a 27.69% increase compared to ¥243.60 million in 2020[23]. - The total assets at the end of 2021 were approximately ¥1.71 billion, reflecting a 3.99% increase from ¥1.65 billion at the end of 2020[23]. - The net cash flow from operating activities for 2021 was approximately ¥43.50 million, a significant increase of 2,643.40% compared to ¥1.59 million in 2020[23]. - The company achieved operating revenue of 311.06 million yuan, a year-on-year increase of 27.69%[35]. - The net cash flow from operating activities increased by 2,643.40% to ¥43,496,009.09 compared to the previous period, primarily due to the acquisition of Vernalis in December 2020, which significantly expanded the scope of operations[152]. Research and Development - The company invested RMB 200 million in R&D, focusing on protein degradation technologies and high-throughput screening methods[12]. - The company is focused on expanding its research and development capabilities, particularly in high-throughput sequencing and drug discovery technologies[15]. - The company has synthesized over 1 trillion structurally diverse DNA-encoded compounds, demonstrating its capability in identifying lead compounds for known and emerging biological targets[39]. - The company has developed a robust nucleic acid drug research platform, leveraging its expertise in RNA interference (RNAi) technology and nucleic acid chemistry[76]. - The company has established a comprehensive nucleic acid drug development platform, enhancing its capabilities in RNA interference technology and drug delivery systems[115]. - The company has completed screening for 47 different target types, including challenging targets, showcasing its advanced capabilities in drug discovery[112]. - The company has developed a one-stop drug optimization system covering various technical aspects, including recombinant protein expression and pharmacokinetics[82]. - The company has established partnerships with two leading research institutions to accelerate innovation and product development[200]. Market Expansion and Strategy - The company is expanding its market presence in Europe, targeting a 30% increase in market share by 2023[12]. - The company is actively pursuing market expansion in Southeast Asia, targeting a 30% increase in market share within the next two years[194]. - The company plans to enhance its core technologies, including expanding the DEL library and improving the efficiency of small molecule screening, to maintain its industry-leading position[174]. - The company aims to construct a high-standard new drug R&D platform to accelerate the clinical advancement of new drug projects and increase revenue through project transfers[176]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 1 billion RMB earmarked for potential deals[200]. - A strategic acquisition of a biotech firm was completed, enhancing the company's capabilities in mRNA drug development[13]. - A strategic acquisition was announced, with the company acquiring a competitor for $200 million, expected to enhance its product offerings[192]. Risks and Compliance - The company has detailed various operational risks and corresponding mitigation strategies in the report[4]. - The company has a comprehensive risk statement regarding forward-looking statements, highlighting potential discrepancies due to various factors[6]. - The company has no non-operating fund occupation by controlling shareholders or related parties[7]. - There are no violations of decision-making procedures regarding external guarantees[7]. - The company faces risks related to new drug development failures, particularly with projects targeting new biological targets[123]. - The company is exposed to foreign exchange risks due to a high proportion of revenue from overseas, primarily in USD and EUR[127]. Human Resources and Governance - The company employs 391 R&D personnel, with 96.42% holding a bachelor's degree or higher, including 86 PhDs and 133 master's degree holders[37]. - The company has established a governance structure that includes a board of directors, supervisory board, and management team, ensuring clear responsibilities and effective operations[182]. - The total remuneration for the chairman and general manager, Jin Li, was reported at 335.38 million CNY for the reporting period[188]. - The average age of the key executives is 46 years, suggesting a balance of experience and innovation[190]. - The company has seen a delay in the appointment of several key positions, which may impact future operations[190]. Future Outlook - The company provided a forward-looking guidance of 20% revenue growth for the next fiscal year, projecting revenues to reach RMB 1.44 billion[12]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[200]. - The company plans to implement new marketing strategies aimed at increasing customer engagement by 40%[192]. - The company is committed to sustainability initiatives, aiming to reduce carbon emissions by 20% over the next three years[193].

成都先导药物开发股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2022 年第一季度报告 证券代码：688222 证券简称：成都先导 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人 JIN LI（李进）、主管会计工作负责人胡春艳及会计机构负责人（会计主管人员）邓 飞明保证季度报告中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | | 本报告期比上年 | | --- | --- | --- | --- | | | | | 同期增减变动幅 | | | | | 度(%) | | 营业收入 | | 72,465,855.95 | 4.77 | | 归属于上市公司股东的净利润 | | -7,088,441.60 | -222.60 | | 归属 ...

Financial Performance - The company's operating revenue for Q3 2021 was ¥73,169,078.08, representing an increase of 86.95% compared to the same period last year[5]. - The net profit attributable to shareholders for the same period was ¥9,034,650.49, with a year-to-date increase of 103.24% to ¥29,692,579.59[5]. - Basic earnings per share for Q3 2021 was ¥0.02, with a year-to-date increase of 75.00% to ¥0.07[6]. - In the first nine months of 2021, the company achieved operating revenue of RMB 227.31 million, representing a year-on-year growth of 80.50%[16]. - The net profit attributable to shareholders increased by 103.24% year-on-year, with a net profit excluding non-recurring gains and losses rising by 15,632.33%[16]. - The total comprehensive income for the third quarter of 2021 was CNY 25,718,921.05, compared to CNY 15,287,160.29 in the same period of 2020, representing a year-over-year increase of approximately 68.5%[27]. - Basic earnings per share increased to CNY 0.07 from CNY 0.04, reflecting a 75% growth in profitability[27]. Research and Development - Total R&D investment for Q3 2021 was ¥17,661,537.97, a decrease of 37.73% compared to the same period last year[6]. - R&D investment as a percentage of operating revenue decreased by 48.33 percentage points to 24.14% in Q3 2021[6]. - The company has established multiple deep collaborations in drug research and development with various biotech firms, including UPPTHERA and BioAge[17]. - A new molecular structure co-developed with FORMA received registration certification from the American Chemical Society[17]. - The company is advancing its research on artificial intelligence applications in drug discovery, collaborating with Tencent AI Lab on a molecular skeleton transition algorithm[17]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,673,795,519.04, reflecting a 1.56% increase from the end of the previous year[6]. - Total liabilities increased to ¥387,574,169.88 in the third quarter of 2021, compared to ¥370,075,489.20 in the same period of 2020, marking an increase of about 4.0%[24]. - The company's total assets as of the end of the third quarter of 2021 amounted to ¥1,673,795,519.04, up from ¥1,648,005,753.49 at the end of 2020[25]. - The total equity attributable to shareholders reached ¥1,286,221,349.16, compared to ¥1,277,930,264.29 in the previous year, reflecting a growth of about 0.6%[24]. - The company’s contract assets increased significantly to ¥19,281,743.68 from ¥3,936,460.48, indicating a growth of approximately 389.5%[23]. Cash Flow - Cash flow from operating activities for the year-to-date period was ¥25,186,166.57, indicating an increase due to higher sales receipts[10]. - The company reported a net cash flow from operating activities growth of 162.99% compared to the previous year[16]. - Cash inflows from operating activities for the first three quarters of 2021 amounted to CNY 246,506,997.61, up from CNY 124,316,725.58 in the same period of 2020, indicating a 98.5% increase[29]. - The net cash flow from operating activities for the third quarter was CNY 25,186,166.57, a significant recovery from a negative cash flow of CNY -39,985,974.19 in the previous year[29]. - Cash inflows from investment activities totaled CNY 1,635,409,651.67, compared to CNY 936,525,126.13 in the same period of 2020, marking a 74.5% increase[30]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,345[12]. - Major shareholders included JIN LI with 20.43% ownership and 拉萨经济技术开发区华博医疗器械有限公司 with 14.08% ownership[12]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[27].

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[1]. - Revenue for the first half of 2021 reached $500 million, representing a 15% increase year-over-year[14]. - The company achieved revenue of 154.14 million yuan, a year-on-year increase of 77.60%, with domestic customer revenue reaching 22.66 million yuan, up 1,362%, accounting for 14.70% of total revenue[101]. - The net profit attributable to shareholders for the first half of 2021 was approximately ¥20.66 million, up 33.88% from ¥15.43 million in the previous year[24]. - The net profit after deducting non-recurring gains and losses was approximately ¥11.73 million, reflecting a 26.51% increase from ¥9.27 million in the previous year[24]. - The company's operating revenue for the first half of 2021 was approximately ¥154.14 million, representing a 77.60% increase compared to ¥86.79 million in the same period last year[23]. - The company reported a significant increase in user data, with a 25% growth in active users compared to the previous year[13]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2021, representing a year-over-year growth of 25%[169]. User Growth - User data showed an increase in active users, with the total number of users growing to 1.2 million, up 30% compared to the same period last year[1]. - User data showed a growth in active users, reaching 10 million, which is a 15% increase compared to the previous period[169]. Future Outlook - The company provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 30% based on current market trends and product demand[1]. - Future guidance indicates an expected revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion[14]. - The company provided a positive outlook for the next quarter, projecting revenue growth of B% and an expected increase in user engagement metrics[160]. - The company plans to invest $50 million in R&D for the development of novel drug candidates over the next year[14]. - New product launches are expected to contribute an additional 300 million in revenue by the end of the year[169]. Market Expansion - The company is expanding its market presence, targeting international markets with a focus on North America and Europe, aiming for a 15% increase in market share by the end of 2022[1]. - The company is expanding its market presence in Asia, targeting a 30% increase in market share within the next two years[14]. - Market expansion strategies include entering E new geographical markets, which are expected to contribute an additional F million in revenue[158]. - The company has plans to enter three new international markets by Q4 2021, aiming for a 10% market share in each[169]. Research and Development - New product development efforts have led to the successful launch of three new drug candidates, which are expected to enter clinical trials by Q4 2021[1]. - The company is investing in new technologies, with a budget of RMB 100 million dedicated to R&D for innovative drug delivery systems[1]. - The company has initiated the development of new mRNA-based therapeutics, aiming to enter clinical trials by Q4 2022[14]. - The company plans to invest heavily in R&D, with a budget allocation of 200 million for new technologies and product development[169]. - The company has approximately 20 internal new drug projects, with 4 projects having received clinical trial approval and currently in different stages of clinical and preclinical trials[32]. Acquisitions and Partnerships - Strategic acquisitions are being considered to enhance the company's research capabilities, with a budget of RMB 200 million allocated for potential mergers and acquisitions in 2021[1]. - A strategic acquisition of a biotech firm was completed, enhancing the company's capabilities in drug discovery and development[14]. - The acquisition of Vernalis (R&D) has positioned the company as a leader in FBDD/SBDD technology, with over 20 years of experience in drug discovery[48]. - The company has established partnerships with leading research institutions to bolster its drug development pipeline, aiming to accelerate time-to-market for new therapies[1]. Risk Management - The management highlighted the importance of risk management strategies in navigating potential market fluctuations and regulatory changes[1]. - The company faces risks related to technology substitution in drug screening methods and the potential for new drug development failures due to the innovative nature of its projects[110]. - The company faces risks related to high customer concentration, which could adversely affect business operations and financial conditions if major clients experience difficulties[112]. Compliance and Governance - The board of directors emphasized the commitment to maintaining transparency and accuracy in financial reporting, ensuring compliance with regulatory standards[1]. - The company has committed to maintaining transparency and accountability in its operations, adhering to all relevant regulations[169]. - The company has not reported any significant violations or penalties against the company or its executives during the period[169]. Environmental Responsibility - The company has established a comprehensive environmental protection system to ensure compliance with regulations during its operations[136]. - The company implemented energy-saving measures, including regulating air conditioning temperatures to reduce electricity consumption[139]. - The company committed to using eco-friendly materials and promoting the use of reusable materials and packaging[139].

Financial Performance - Operating revenue rose by 56.79% to CNY 69,164,316.00 year-on-year[5] - Net profit attributable to shareholders decreased by 33.85% to CNY 5,781,934.11 compared to the same period last year[5] - Basic earnings per share dropped by 50.00% to CNY 0.01 compared to the previous year[5] - Net profit increased by 61.99% to CNY 5,781,934.11 compared to the same period last year, despite the negative impact from the integration of two new UK subsidiaries[15] - Comprehensive income for Q1 2021 totaled CNY 11,129,768.46, compared to CNY 8,364,450.33 in Q1 2020, reflecting an increase of 32.9%[25] - Net profit for Q1 2021 was CNY 5,781,934.11, a decrease of 33.5% from CNY 8,740,267.66 in Q1 2020[25] Cash Flow - The net cash flow from operating activities was CNY 14,094,598.87, a significant improvement from a negative cash flow of CNY -1,897,162.63 in the previous year[5] - Cash flow from operating activities reached CNY 14,094,598.87, a significant improvement from a negative cash flow of CNY -1,897,162.63 in Q1 2020[15] - Cash flow from financing activities improved to CNY -745,785.04 from CNY -5,224,241.78 in Q1 2020, reflecting reduced IPO-related payments[15] Assets and Liabilities - Total assets increased by 2.89% to CNY 1,695,639,358.72 compared to the end of the previous year[5] - The total assets as of March 31, 2021, amounted to CNY 1,695,639,358.72, up from CNY 1,648,005,753.49 at the end of 2020[18] - The total liabilities increased to CNY 407,695,135.23 from CNY 370,075,489.20 at the end of 2020[18] - The company's deferred tax assets decreased by 61.59% to RMB 1,414,997.46, mainly due to profits in Q1 2021 offsetting previously recognized losses[13] - The accounts payable increased by 56.06% to RMB 14,609,507.20, primarily due to increased technical service fees owed by Vernalis[13] Shareholder Information - The total number of shareholders at the end of the reporting period was 7,696[10] - The top shareholder, JIN LI, holds 20.43% of the shares, totaling 81,876,948 shares[11] Research and Development - R&D investment as a percentage of operating revenue decreased by 30.09 percentage points to 20.63%[5] - Research and development expenses decreased by 36.22% to RMB 14,270,243.49, reflecting a shift in focus away from self-developed projects[14] - Research and development expenses for Q1 2021 were CNY 14,270,243.49, down 36.3% from CNY 22,375,778.77 in Q1 2020[24] Operating Costs - Operating costs surged to RMB 35,783,045.16, a 322.85% increase from RMB 8,462,383.89 in the previous year, attributed to a shift towards commercial projects and lower gross margins from Vernalis[14] - Total operating costs for Q1 2021 were CNY 68,611,515.30, up 96.7% from CNY 34,858,761.09 in Q1 2020[24] Other Income and Expenses - Non-recurring gains and losses totaled CNY 2,928,158.85 for the period[9] - The company recognized other income of RMB 3,054,359.81, an 85.87% increase, mainly due to government subsidies received by Vernalis during the reporting period[14] - The financial expenses for Q1 2021 showed a notable increase in interest expenses, which reached RMB 896,516.99, a 506.13% rise compared to RMB 147,907.32 in the previous year[14] Equity - The company's equity attributable to shareholders rose to CNY 1,287,944,223.49, compared to CNY 1,277,930,264.29 at the end of 2020[18]

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the fiscal year 2020, representing a year-over-year increase of 20%[12]. - The company's operating revenue for 2020 was ¥243.6 million, a decrease of 7.80% compared to ¥264.2 million in 2019[23]. - The net profit attributable to shareholders for 2020 was ¥64.0 million, down 46.77% from ¥120.3 million in 2019[23]. - The net cash flow from operating activities was ¥1.6 million, a significant decline of 99.06% compared to ¥168.3 million in 2019[23]. - The company achieved revenue of ¥243,600,479.33, a year-on-year decrease of 7.80% due to the impact of the COVID-19 pandemic[110]. - The net profit attributable to shareholders was CNY 64,023,167.70, down 46.77% year-on-year[133]. - Revenue from the U.S. market decreased by 23.98% to CNY 162,861,701.45, with a gross margin reduction of 2.63 percentage points[137]. - Revenue from the China region reached ¥50,346,892.41, a year-on-year increase of 1,562.11%, accounting for 20.67% of total revenue[110]. Research and Development - The company invested RMB 200 million in R&D for new technologies, focusing on high-throughput screening and structure-based drug design[13]. - The company's R&D expenditure accounted for 41.00% of operating income, an increase of 6.38 percentage points compared to the previous year[25]. - The total R&D investment for the year was ¥99,874,213.34, representing a 9.20% increase from ¥91,461,692.47 in the previous year[91]. - The company has a total of 383 R&D personnel, with 38.64% holding bachelor's degrees and 22.98% holding doctoral degrees[98]. - The company is focused on expanding its product pipeline and enhancing its research capabilities in drug development[22]. - The company has developed a comprehensive drug optimization platform that spans from target gene identification to clinical trial application, integrating multiple technical disciplines[73]. - The company is actively developing nucleic acid drugs, focusing on tumor and autoimmune indications, leveraging its expertise in nucleic acid chemistry[74]. Market Expansion and Strategy - The company is expanding its market presence in Europe, targeting a 30% increase in market share by the end of 2021[12]. - The company provided guidance for 2021, expecting revenue growth of 25% to reach approximately RMB 1.875 billion[12]. - The company plans to expand its marketing service network domestically and internationally to support steady revenue growth[171]. - The company aims to become a global "seed bank" for innovative drugs and a new engine for drug creation, with operations spanning North America, Europe, Asia, and Australia[36]. - The company plans to implement a new strategy for enhancing its intellectual property portfolio, aiming for a 40% increase in patent filings by the end of 2021[13]. Acquisitions and Collaborations - A strategic acquisition of a biotechnology firm was completed, enhancing the company's capabilities in drug development and research[12]. - The company completed the acquisition of Vernalis, a leader in fragment-based drug discovery and design technology, enhancing its drug discovery capabilities[35]. - The company acquired 100% equity of Vernalis for $26,650,459 (approximately RMB 173,045,462.94) on October 11, 2020, completing the transaction by December 2, 2020[100]. - The company has formed deep collaborations with several biopharmaceutical companies and academic partners, enhancing its drug development capabilities[71]. Risks and Challenges - The company emphasizes the importance of investor caution regarding investment risks[6]. - The company has outlined potential risks in the "Discussion and Analysis of Operating Conditions" section[4]. - The company is exposed to risks of new drug development failures, particularly due to the focus on new targets and mechanisms[126]. - The ongoing COVID-19 pandemic poses a risk to the company's main business operations due to potential restrictions on client activities[130]. - The company faces risks from U.S.-China trade tensions and currency fluctuations, which could adversely affect its operations[131]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Deloitte Huayong[5]. - There are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company does not have any special arrangements for corporate governance[8]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of listing[179]. - The company will report any changes in shareholding by its actual controllers and senior management during their tenure[181]. Dividend Policy - The company plans to distribute a cash dividend of 0.5 yuan per 10 shares, totaling 20,034,000 yuan, which accounts for 31.29% of the net profit attributable to shareholders[5]. - The company has a cash dividend policy that protects the rights of minority investors and complies with relevant regulations[175]. - The profit distribution policy emphasizes a minimum annual cash dividend of 10% of the distributable profit for the first three years post-IPO, provided certain financial conditions are met[194].

Financial Performance - Operating revenue decreased by 19.06% to CNY 125,929,094.01 for the first nine months compared to the same period last year[6]. - Net profit attributable to shareholders decreased by 80.34% to CNY 14,609,816.84 for the first nine months compared to the same period last year[6]. - The weighted average return on net assets decreased by 15.82 percentage points to 1.59%[6]. - Basic earnings per share decreased by 80.95% to CNY 0.04[7]. - Other income fell by 69.39% to RMB 14,725,962.60, as there were no significant government grants in 2020 compared to the previous year[17]. - The net profit attributable to shareholders for the first three quarters of 2020 was RMB 14,609,816.84, a decrease of 80.34% compared to RMB 74,309,852.71 in the same period of 2019[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 82,255.94, down 99.75% from RMB 33,471,642.35 in the previous year[18]. - The company's operating revenue for the first three quarters of 2020 was RMB 125,929,100, a year-on-year decrease of 19.06% due to the impact of the global pandemic[18]. - The net profit for Q3 2020 was ¥2,305,880.94, compared to a net profit of ¥20,024,870.72 in Q3 2019, indicating a significant decline[35]. - The total profit for Q3 2020 was reported at -¥2,742,232.92, contrasting with a profit of ¥20,967,450.38 in Q3 2019[35]. Assets and Liabilities - Total assets increased by 106.07% to CNY 1,309,248,582.95 compared to the end of the previous year[6]. - Total liabilities decreased to RMB 83,397,570.68 from RMB 123,581,043.87 in the previous year[24]. - The total equity attributable to shareholders increased to RMB 1,225,851,012.27 from RMB 511,772,243.86 at the end of 2019[24]. - Total assets as of September 30, 2020, reached CNY 1,345,270,024.87, a significant increase from CNY 661,373,096.91 as of December 31, 2019[27]. - Total liabilities decreased to CNY 69,191,037.64 from CNY 109,804,355.96, indicating improved financial stability[28]. - The company's equity increased to CNY 1,276,078,987.23 from CNY 551,568,740.95, reflecting a strong capital position[28]. Cash Flow - The company reported a net cash flow from operating activities of CNY -39,985,974.19 for the first nine months, a decrease of 127.77% compared to the same period last year[6]. - Cash flow from operating activities for the first three quarters of 2020 was CNY 124,316,725.58, down 55.6% from CNY 279,979,552.98 in the same period of 2019[39]. - Net cash flow from operating activities was negative at CNY -39,985,974.19, contrasting with a positive CNY 143,996,728.00 in the prior year[39]. - Cash inflow from investment activities totaled CNY 936,525,126.13, a substantial increase from CNY 505,561,822.64 in the previous year[39]. - Cash outflow for investment activities was CNY 1,403,497,527.91, compared to CNY 575,917,339.50 in the same period last year[40]. - Net cash flow from investment activities was negative at CNY -466,972,401.78, worsening from CNY -70,355,516.86 in 2019[40]. - Cash flow from financing activities generated CNY 766,971,607.68, with a net cash flow of CNY 696,631,154.92 after outflows[40]. Research and Development - R&D expenses accounted for 59.46% of operating revenue, an increase of 21.9 percentage points compared to the previous year[7]. - Research and development expenses increased by 28.11% to RMB 74,873,400 in the first three quarters of 2020[18]. - R&D expenses for the first three quarters of 2020 totaled CNY 74,873,434.98, up 28.4% from CNY 58,443,094.96 in the same period of 2019[30]. - Research and development expenses increased to ¥26,272,231.73 in Q3 2020, up from ¥18,710,133.90 in Q3 2019, reflecting a 40% increase[35]. Shareholder Information - The total number of shareholders reached 7,763 by the end of the reporting period[12]. - The largest shareholder, LI.JIN, holds 20.43% of the shares, totaling 81,876,948 shares[12]. Inventory and Prepayments - Prepayments surged by 410.58% to RMB 14,457,675.81, primarily due to increased advance payments for materials and outsourced services[16]. - Inventory rose by 78.83% to RMB 23,413,236.77, attributed to higher raw material purchases[16]. - Inventory levels rose to CNY 23,413,236.77 from CNY 13,092,557.77, indicating increased production or stockpiling[26]. Compliance and Accounting Standards - The company implemented new revenue and leasing standards starting January 1, 2020, affecting the financial statements[47]. - The company is focused on adjusting financial reporting in compliance with new accounting standards, enhancing transparency and accuracy[47]. - The company adopted new revenue recognition standards starting January 1, 2020, impacting financial reporting[52]. - The company is committed to compliance with updated accounting standards as of 2020[52].